EMBO reports

DGCR8 is essential for tumor progression following PTEN loss in the prostate.

EMBO reports

Belair CD, Paikari A, Moltzahn F, Shenoy A, Yau C, Dall'Era M, Simko J, Benz C, Blelloch R